As per your post he noted that Revenue in 2018 was less than in 2017. His criteria would signal alarm.Slight fall in capital revenue due to the adoption of Trophon 2
Total sales of Nanosonics shares reflect a 10%reduction in capital revenue on the prior year, Nanosonics points out that thisis associated with the earlier than anticipated regulatory approval of trophon2with North America and European, and subsequent run down of Trophon EPR (thefirst generation) inventory by distributors. Also, some customers deferringpurchase pending launch of trophon2 in Q1 of FY19. However, the increase ofsales of consumables and service were up 25% reflecting the increasing installedbase, demonstrating strong growth in the annuity revenue profile.
As per your post he noted that Revenue in 2018 was less than in...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NAN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.22 |
Change
-0.040(1.23%) |
Mkt cap ! $1.087B | |||
| Open | High | Low | Value | Volume |
| $3.21 | $3.25 | $3.20 | $404.7K | 125.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1285 | $3.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.25 | 2424 | 2 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| NAN (ASX) Chart |
